Sponsor or institution

Clinical trials and research at Evopoint Biosciences Inc.

• 7Clinical trials
• 1Country

Newest trials

All recruiting trials (7)

• XNW28012 in metastatic pancreatic cancer after standard therapy

  This study tests XNW28012 plus standard care against a matched control to see if it can help people with metastatic pancreatic cancer who have already tried two prior treatments.

  Recruiting at 48 sites Phase 3 Evopoint Biosciences Inc. · Shanghai, Shanghai Municipality and 47 other locations · NCT07823049

• XNW5004 with CHOP/CHOEP in Untreated Peripheral T-Cell Lymphoma

  This study tests XNW5004 together with CHOP or CHOEP in adults with newly diagnosed peripheral T-cell lymphoma to see if the combination is safe and active.

  Recruiting Phase 1/2 Evopoint Biosciences Inc. · Shanghai, Shanghai Municipality · NCT07730515

• XNW5004 tablets for relapsed or refractory EZH2 wild-type follicular lymphoma

  This trial will try XNW5004 tablets in adults with relapsed or refractory EZH2 wild-type follicular lymphoma who have had at least three prior systemic treatments to see if the drug shrinks tumors and is tolerable.

  Recruiting Phase 2 Evopoint Biosciences Inc. · Beijing, Beijing Municipality · NCT07545603

• Evaluating XNW29016 Tablets for Advanced Solid Tumors After Standard Treatment Failure

  This study is testing if XNW29016 tablets can help people with advanced solid tumors who haven't responded to regular treatments.

  Recruiting Phase 1/2 Evopoint Biosciences Inc. · Beijing, Beijing Municipality · NCT06987500

• Testing XNW28012 in patients with advanced solid tumors who have not responded to standard treatments

  This study is testing a new treatment called XNW28012 in patients with advanced solid tumors who haven't had success with regular cancer therapies to see if it can help them.

  Recruiting at 24 sites Phase 1/2 Evopoint Biosciences Inc. · Hefei, Anhui and 23 other locations · NCT06799637

• XNW5004 versus Chidamide for relapsed or refractory peripheral T-cell lymphoma

  This will test whether XNW5004 tablets work better than Chidamide for adults (18–70) whose peripheral T-cell lymphoma has returned or not responded to prior treatments.

  Recruiting Phase 3 Evopoint Biosciences Inc. · Beijing, Beijing Municipality · NCT06776952

• Treatment of advanced prostate cancer with XNW5004 and enzalutamide

  This study tests if combining the drugs XNW5004 and enzalutamide can help men with advanced prostate cancer that hasn't responded to other hormone treatments.

  Recruiting at 2 sites Phase 1/2 Evopoint Biosciences Inc. · Jinan, Shandong and 1 other locations · NCT06702995

Quick answers

How many clinical trials run by Evopoint Biosciences Inc. are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 4, Phase 3: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →